TENX Stock Price, Analysis & Fundamentals

Analysis

Tenax Therapeutics, Inc. is a biotechnology company within the healthcare sector. With a market capitalization of $76.92M and only 4 employees, it is a relatively small player in its industry. The company's financial health is concerning, with zero gross margin, operating margin, and profit margin. This suggests that the company may be struggling to generate revenue or manage expenses effectively. The negative net income of -$43.32 million (TTM) further underscores these challenges. Meanwhile, the free cash flow stands at -$12.11 million, indicating a significant outflow of funds from operations. The company's valuation is also noteworthy, with a forward P/E ratio of -7.86 and a price-to-book ratio of 5.15. This may suggest that investors are currently undervaluing or have concerns about the company's prospects for future profitability.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Visit website →

TENX

Price History (1Y)

Analysis

About Tenax Therapeutics, Inc.

Key Statistics

Company Info